S&P 500
(0.32%) 5 116.17 points
Dow Jones
(0.38%) 38 386 points
Nasdaq
(0.35%) 15 983 points
Oil
(-0.01%) $82.62
Gas
(0.79%) $2.05
Gold
(-0.54%) $2 345.00
Silver
(-1.03%) $27.38
Platinum
(-0.28%) $958.80
USD/EUR
(0.08%) $0.933
USD/NOK
(0.13%) $11.00
USD/GBP
(0.01%) $0.796
USD/RUB
(1.56%) $93.31

Echtzeitaktualisierungen für Biomarin Pharmaceutical [BMRN]

Börse: NASDAQ Sektor: Healthcare Industrie: Biotechnology
BUY
65.31%
return 6.27%
SELL
36.00%
return 14.64%
Zuletzt aktualisiert29 Apr 2024 @ 22:00

1.51% $ 82.13

KAUFEN 277 min ago

@ $82.88

Ausgestellt: 29 Apr 2024 @ 20:37


Rendite: -0.90%


Vorheriges Signal: Apr 29 - 15:33


Vorheriges Signal: Verkaufen


Rendite: 0.99 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):
Profile picture for Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...

Stats
Tagesvolumen 1.92M
Durchschnittsvolumen 1.55M
Marktkapitalisierung 15.59B
EPS $0 ( 2024-04-24 )
Nächstes Ertragsdatum ( $0.610 ) 2024-07-29
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 77.48
ATR14 $2.40 (2.92%)
Insider Trading
Date Person Action Amount type
2024-04-12 Bienaime Jean Jacques Buy 20 000 Common Stock
2024-04-11 Bienaime Jean Jacques Sell 20 000 Common Stock
2024-04-12 Bienaime Jean Jacques Sell 20 000 Common Stock
2024-04-11 Bienaime Jean Jacques Sell 20 000 Stock Option (Right to Buy Common Stock)
2024-04-12 Bienaime Jean Jacques Sell 20 000 Stock Option (Right to Buy Common Stock)
INSIDER POWER
25.84
Last 93 transactions
Buy: 972 265 | Sell: 563 201

Volumen Korrelation

Lang: -0.95 (very strong negative)
Kurz: 0.21 (neutral)
Signal:(49) Neutral

Biomarin Pharmaceutical Korrelation

10 Am meisten positiv korreliert
MMAC0.923
RMRM0.916
FREQ0.89
ABST0.889
IMPL0.889
SGBX0.887
TTOO0.887
INFI0.885
SBBP0.884
CFV0.884
10 Am meisten negativ korreliert
APOP-0.956
ICON-0.907
RDUS-0.893
MIND-0.88
TRMD-0.879
WRLD-0.878
SYKE-0.875
SOUN-0.873
MGTX-0.873
FEYE-0.869

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Biomarin Pharmaceutical Korrelation - Währung/Rohstoff

The country flag 0.22
( neutral )
The country flag -0.62
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.10
( neutral )
The country flag 0.27
( neutral )
The country flag -0.22
( neutral )

Biomarin Pharmaceutical Finanzdaten

Annual 2023
Umsatz: $2.42B
Bruttogewinn: $1.84B (76.15 %)
EPS: $0.890
FY 2023
Umsatz: $2.42B
Bruttogewinn: $1.84B (76.15 %)
EPS: $0.890
FY 2022
Umsatz: $2.10B
Bruttogewinn: $1.61B (76.92 %)
EPS: $0.760
FY 2021
Umsatz: $1.85B
Bruttogewinn: $1.38B (74.52 %)
EPS: $-0.354

Financial Reports:

No articles found.

Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.